Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects

NCT05806177 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: AD16 30mg、40mg
DRUG: AD16 Placebo 30mg、40mg

Sponsor

South China Center For Innovative Pharmaceuticals

Collaborators

[object Object]